Advances in study of glucocorticoid receptor induced insulin resistance and its antagonists

Abstract

Abstract: Glucocorticoids are among those most important hormones that maintain the energy metabolic homeostasis within body.The actions of glucocorticoids on target tissues, such as liver and adipose tissue, are not only dependent on circulating glucocorticoid levels but also on glucocorticoid receptor expression.The elevated level of circulating glucocorticoid caused by exogenous or endogenous reasons may contribute to insulin resistance and the other metabolic syndrome such as dyslipidemia, visceral obesity and hypertension.This review summarizes recent advances in the study of glucocorticoid receptormediated insulin resistance and its antagonists.

Key words: glucocorticoid, glucocorticoid receptor, insulin resistance, glucocorticoid receptor antagonist

CLC Number:

R587.1

LIANG Ying, DING Qi-long. Advances in study of glucocorticoid receptor induced insulin resistance and its antagonists[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2007, 12(2): 147-151.

References

[1] Watts LM, Manchem VP, Leedom TA, et al. Reduction of he- patic and adipose tissue glucocorticoid receptor expression with antisense oligonucleotides improves hyperglycemia and hyperlipidemia in diabetic rodents without causing sy stemic glucocorticoid antagonism[J]. Diabetes, 2005;54:1846-1853.
[2] Masuzaki H, Paterson J, Shinyama H, et al. A transgenic model of visceral obesity and the metabolic syndrome[J]. Science, 2001;294:2166-2170.
[3] Liu YJ, Nakagawa Y, Wang Y, et al. Increased glucocorticoid receptor and 11β-Hydroxysteroid dehydrogenase type 1 expression in hepatocytes may contribute to the phenotype of type 2 diabetes in db db mice[J]. Diabetes, 2005;54:32-40.
[4] Reynolds RM, Chapman KE, Seckl JR.Skeletal muscle glucocorticoid receptor density and insulin resistance[J]. J Am Med Assoc, 2002;287:2505-2506.
[5] Friedman TC, Mastorakos G, Newman TD, et al. Carbohydrate and lipid metabolism in endogenous hypercortisolism:shared features with metabolic syndrome X and NIDDM[J]. Endocr J, 1996;43:645-655.
[6] Pujols L, Mullol J, Roca-Ferrer J, et al. Expression of glucocorticoid α-and β-isoforms in human cells and tissues[J]. Am J Physiol Cell Phy siol, 2002;283:1324-1331.
[7] Oakley RH, Sar M, Cidlowski JA.The human glucocorticoid receptor β isoform:expression, biochemical properties, and putative function[J]. J Biol Chem, 1996;271:9550-9559.
[8] Hecht K, Carlstedt-Duke J, Stierna P, et al. Evidence that the β-isoform of the human glucocorticoid receptor does not act as a physiologically significant repressor[J]. J Biol Chem, 1997;272:26659-26664.
[9] Oakley RH, Jewell CM, Yudt MR, et al. The dominant negative activity of the human glucocorticoid receptor β isoform. Specificity and mechanisms of action[J]. J Biol Chem, 1999; 274:27857-27866.
[10] de Lange P, Segeren CM, Koper JW, et al. Expression in hematological malignancies of a glucocorticoid receptor splice variant that augments glucocorticoid receptor-mediated effects in transfected cells[J]. Cancer Res, 2001;61:3937-3941.
[11] Opherk C, Tronche F, Kellendonk C, et al. Inactivation of the glucocorticoid receptor in hepatocytes leads to fasting hypoglycemia and ameliorates hyperglycemia in streptozotocin-induced diabetes mellitus[J]. Mol Endocrinol, 2004;18:1346-1353.
[12] Whorwood CB, Donovan SJ, Wood PJ, et al. Regulation of glucocorticoid receptor αand β isoforms and type I 11β-Hydroxysteroid dehydrogenase expression in human skeletal muscle cells:A key role in the pathogenesis of insulin resistance[J] ? J Clin EndocrinolMetab, 2001;86:2296-2308.
[13] Whorwood CB, Donovan SJ, Flanagan D, et al. Increased glucocorticoid receptor expression in human skeletal muscle cells may contribute to the pathogenesis of the metabolic syndrome[J]. Diabetes, 2002;51:1066-1075.
[14] Boullu-Ciocca S, Paulmyer-Lacroix O, Fina F, et al. Expression of the mRNAs coding for the glucocorticoid receptor isoforms in obesity[J]. Obes Res, 2003;11:925-929.
[15] Hagendorf A, Koper JW, de Jong FH, et al. Expression of the human glucocorticoid receptor splice variants α, β, and P in peripheral blood mononuclear leukocytes in healthy controls and in patients with hyper- and hypocortisolism[J]. J Clin Endocrinol Metab, 2005;90:6237-6243.
[16] Friedman JE, Sun Y, Ishizuka T, et al. Phosphoenolpyruvate carboxykinase (GTP) gene transcription and hypergly cemia are regulated by glucocorticoids in genetically obese db db transgenic mice[J]. J Biol Chem, 1997;272:31475-31481.
[17] Pariante CM, Pearce BD, Pisell TL, et al. The steroid receptor antagonists RU40555 and RU486 activate glucocorticoid receptor translocation and are not excreted by the steroid hormones transporter in L929 cells[J]. J Endocrinol, 2001;169:309-320.
[18] Chrousos GP.Is 11β-hydroxysteroid dehydrogenase type 1 a good therapeutic target for blockade of glucocorticoid actions[J] ? PNAS, 2004;101:6329-6330.
[19] Chrousos GP, Detera-wadleigh SD, KarlM.Syndromes of Glucocorticoid Resistance[J]. Ann Intern Med, 1993;119:1113-1124.
[20] Jacobson PB, von Geldern TW, hman L, et al. Hepatic glucocorticoid receptor antagonism is sufficient to reduce elevated hepatic glucose output and improve glucose control in animal models of type 2 diabetes[J]. J Pharmacol Exp Ther, 2005;314:191-200.
[21] Lamberts SW, Koper JW, de Jong FH.The endocrine effects of long-term treatment with mifepristone (RU 486)[J]. J Clin EndocrinolMetab, 1991;73:187-191.
[22] Schulz M, Eggert M, Baniahmad A, et al. RU486-induced Glucocorticoid Receptor Agonism Is Controlled by the Receptor N Terminus and by Corepressor Binding[J]. J Biol Chem,2002;277:26238-26243.
[23] Miner JN, Ty ree C, Hu JL, et al. A Nonsteroidal Glucocorticoid Receptor Antagonist[J]. Mol Endocrinol, 2003;17:117-127.
[24] Liu YJ, Yan CY, Wang Y, et al. Liver X receptor agonist T0901317 inhibition of glucocorticoid receptor expression in hepatocytes may contribute to the amelioration of diabetic syndrome in db db mice[J]. Endocrinology, 2006;147:5061-5068.
[25] Link JT, Sorensen B, Patel J, et al. Antidiabetic activity of passive nonsteroidal glucocorticoid receptor modulators[J]. J Med Chem, 2005;48:5295-5304.